| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-302) | 1L metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Aumolertinib - (AENEAS) | CNS metastases and EGFR-mutated non-small cell lung cancer (NSCLC) | Phase 3 | Trial Completed | Oral | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-301) | Stage III Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Completed | Intravenous | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-301) | Stage III Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Completed | Intravenous | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-301) | Stage III Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Completed | Intravenous | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Aumolertinib - (AENEAS) | CNS metastases and EGFR-mutated non-small cell lung cancer (NSCLC) | Phase 3 | Trial Completed | Oral | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-302) | 1L metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Daraxonrasib - (RASolute 304) | Resectable pancreatic ductal adenocarcinoma (PDAC) | Phase 3 | Enrollment Initiation | Oral | Oncology |